Colorectal cancer

Genetic Technologies Reports Q1 FY22 Results

Monday, October 25, 2021 - 1:30pm

The Multi-Test is a Predictive Panel Risk Test to cover six common cancers which account for ~70% of annual morbidities.

Key Points: 
  • The Multi-Test is a Predictive Panel Risk Test to cover six common cancers which account for ~70% of annual morbidities.
  • Phase one launch to include Breast Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Coronary Artery Disease and Type-2 Diabetes.
  • Commenting on the quarter, CEO Simon Morriss stated: This past quarter demonstrates the forward trajectory and momentum Genetic Technologies has established.
  • Authorised for release by the Board of Genetic Technologies Limited.

Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer

Monday, October 25, 2021 - 1:05pm

Additionally, the blood-based test identified 90% of patients with asymptomatic Stage 1 or 2 CRC, suggesting the test may have meaningful performance in an average-risk screening population.

Key Points: 
  • Additionally, the blood-based test identified 90% of patients with asymptomatic Stage 1 or 2 CRC, suggesting the test may have meaningful performance in an average-risk screening population.
  • The LUNAR-2 blood test aims to detect early-stage cancer in screen-eligible asymptomatic adults from a simple blood draw.
  • Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors

Monday, October 25, 2021 - 1:55pm

Dr. Tova specializes in treating cancer with radiation, using radiation therapy to treat a wide variety of cancers.

Key Points: 
  • Dr. Tova specializes in treating cancer with radiation, using radiation therapy to treat a wide variety of cancers.
  • Dr. Tova is certified by the American Board of Radiology (ABR), and currently serves as Director of the Radiotherapy Institute at Ziv Hospital in Israel.
  • Company Director and Head of Advisory Board, Dr. Gil Feiler, commented: "It is with great pleasure that I welcome Dr. Yonina Tova to our Advisory Board.
  • For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Freenome Shows Continued Leadership in Colorectal Cancer Research

Monday, October 25, 2021 - 1:00pm

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology (ACG) annual meeting that underscores their commitment to improving colorectal cancer (CRC) screening.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology (ACG) annual meeting that underscores their commitment to improving colorectal cancer (CRC) screening.
  • Freenome is developing a CRC screening test using a routine blood draw to detect cancer in its earliest stages.
  • PREEMPT CRC, Freenome's multi-center clinical study on colorectal cancer, is in the final stages of enrollment.
  • Freenome is a biotechnology company with the most comprehensive multiomics platform for early cancer detection using a routine blood draw.

Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21

Friday, October 22, 2021 - 12:00pm

EANM is the largest organization dedicated to nuclear medicine in Europe and represents more than 9,000 specialists from 41 different countries.

Key Points: 
  • EANM is the largest organization dedicated to nuclear medicine in Europe and represents more than 9,000 specialists from 41 different countries.
  • Our preclinical studies with antibody-drug conjugate forms of ifabotuzumab have shown promising results.
  • The Olivia Newton-John Cancer Research Institute plans to conduct a Phase 1b dose-escalation and imaging study in non-CNS solid tumors that is scheduled to begin in early 2022.
  • We look forward to supporting our valued partners in Australia as they advance research of ifabotuzumab into solid tumors.

QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities

Friday, October 22, 2021 - 11:00am

QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchesters CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.

Key Points: 
  • QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchesters CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.
  • The move into the new facility will help us write the next chapter of this success story.
  • Health Innovation Manchester unites the regions spectrum of public, academic and clinical resources.
  • It is meant to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.

Servier announces outcome from the primary analysis of the Phase III SOLSTICE trial assessing LONSURF® (trifluridine/tipiracil) + bevacizumab in a 1st line setting for patients with unresectable mCRC non-eligible for intensive therapy

Friday, October 22, 2021 - 8:00am

SOLSTICE was designed to evaluate the superiority of LONSURF (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.

Key Points: 
  • SOLSTICE was designed to evaluate the superiority of LONSURF (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.
  • D., Head of Late Stage and Life Cycle Management, and Deputy Head Oncology and Immuno-Oncology Therapeutic Area, Servier.
  • The clinical value of LONSURF in its current indications remains unchanged, and the ongoing Phase III SUNLIGHT trial (LONSURF + bevacizumab versus LONSURF in 3rd line mCRC) is proceeding as planned.
  • SOLSTICE is an open-label, randomized, multicentre Phase III trial in 856 unresectable metastatic colorectal cancer patients who are not candidates for, or do not require, intensive therapy.

EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX

Thursday, October 21, 2021 - 1:33pm

TEL AVIV, IsraelandBETHESDA, Md., Oct. 21, 2021 /PRNewswire/ --Cannabics Pharmaceuticals Inc. (OTC: CNBX),a global leader in the development of cancer related cannabinoid-based medicine, announced today that EDISON Group issued a Healthcare QuickView publication on the company prepared by Analyst Will Manuel.

Key Points: 
  • TEL AVIV, IsraelandBETHESDA, Md., Oct. 21, 2021 /PRNewswire/ --Cannabics Pharmaceuticals Inc. (OTC: CNBX),a global leader in the development of cancer related cannabinoid-based medicine, announced today that EDISON Group issued a Healthcare QuickView publication on the company prepared by Analyst Will Manuel.
  • Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine.
  • For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
  • For more information about Cannabics:

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies

Wednesday, October 20, 2021 - 9:05pm

HAMILTON, Ontario and BOSTON, Oct. 20, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies (TATs) at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.

Key Points: 
  • These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.
  • Data from preclinical studies of FPI-1966, a TAT designed to target and deliver actinium-225 to cancer cells expressing FGFR3, were presented in an oral presentation titled, "FGFR3 Targeted Alpha Therapeutic [225Ac]-FPI-1966 induces regression in preclinical bladder xenograft model".
  • Further, the data showed therapeutic efficacy of FPI-1966 at both single and multiple doses in a preclinical bladder cancer xenograft model.
  • Data from preclinical studies of FPI-2059, a TAT designed to target and deliver actinium-225 to cancer cells expressing neurotensin receptor 1 (NTSR1), were presented in an oral presentation titled "NTSR1 Targeted Alpha Therapeutic [225Ac]-FPI-2059 induces regression in preclinical colorectal xenograft model".

Oncoinvent to Present Four Posters at the 34th Annual Congress of the European Association of Nuclear Medicine

Wednesday, October 20, 2021 - 9:00pm

We look forward to the continued clinical development of Radspherin in colorectal and ovarian cancer patients suffering from peritoneal carcinomatosis.

Key Points: 
  • We look forward to the continued clinical development of Radspherin in colorectal and ovarian cancer patients suffering from peritoneal carcinomatosis.
  • Ovarian cancer mouse models were treated with 224Ra-CaCO3-MP (5 mg, 14-22 kBq/animal) one day following tumor cell inoculation.
  • When 224Ra-CaCO3-MP was administered in combination with carboplatin-PLD, survival was significantly prolonged compared to mice that received carboplatin-PLD alone.
  • Radspherin is in two ongoing Phase 1 studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.